431 related articles for article (PubMed ID: 24658074)
1. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA.
Thierry AR; Mouliere F; El Messaoudi S; Mollevi C; Lopez-Crapez E; Rolet F; Gillet B; Gongora C; Dechelotte P; Robert B; Del Rio M; Lamy PJ; Bibeau F; Nouaille M; Loriot V; Jarrousse AS; Molina F; Mathonnet M; Pezet D; Ychou M
Nat Med; 2014 Apr; 20(4):430-5. PubMed ID: 24658074
[TBL] [Abstract][Full Text] [Related]
2. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
[TBL] [Abstract][Full Text] [Related]
3. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.
Spindler KL; Pallisgaard N; Vogelius I; Jakobsen A
Clin Cancer Res; 2012 Feb; 18(4):1177-85. PubMed ID: 22228631
[TBL] [Abstract][Full Text] [Related]
4. Cross-platform comparison of next-generation sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patients.
Xu X; Huang F; Cao M; Chen X; Wang H; Jiang H; Yu Y; Shen M; Yang Y; Wang B; Liu T; Guo W
J Clin Lab Anal; 2021 Sep; 35(9):e23818. PubMed ID: 34403504
[TBL] [Abstract][Full Text] [Related]
5. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.
Mostert B; Jiang Y; Sieuwerts AM; Wang H; Bolt-de Vries J; Biermann K; Kraan J; Lalmahomed Z; van Galen A; de Weerd V; van der Spoel P; Ramírez-Moreno R; Verhoef C; Ijzermans JN; Wang Y; Gratama JW; Foekens JA; Sleijfer S; Martens JW
Int J Cancer; 2013 Jul; 133(1):130-41. PubMed ID: 23233388
[TBL] [Abstract][Full Text] [Related]
6. Detection of mutations in circulating cell-free DNA in relation to disease stage in colorectal cancer.
Liebs S; Keilholz U; Kehler I; Schweiger C; Haybäck J; Nonnenmacher A
Cancer Med; 2019 Jul; 8(8):3761-3769. PubMed ID: 31134762
[TBL] [Abstract][Full Text] [Related]
7. Duplex reverse-hybridization assay for the simultaneous detection of KRAS/BRAF mutations in FFPE-extracted genomic DNA from colorectal cancer specimens.
Buxhofer-Ausch V; Ausch C; Zeillinger R; Oberkanins C; Dandachi N; Reiner-Concin A; Kriegshäuser G
Dis Markers; 2013; 34(3):171-7. PubMed ID: 23324583
[TBL] [Abstract][Full Text] [Related]
8. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
[TBL] [Abstract][Full Text] [Related]
9. Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients.
Mohamed Suhaimi NA; Foong YM; Lee DY; Phyo WM; Cima I; Lee EX; Goh WL; Lim WY; Chia KS; Kong SL; Gong M; Lim B; Hillmer AM; Koh PK; Ying JY; Tan MH
Mol Oncol; 2015 Apr; 9(4):850-60. PubMed ID: 25605225
[TBL] [Abstract][Full Text] [Related]
10. Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls.
Lamy A; Blanchard F; Le Pessot F; Sesboüé R; Di Fiore F; Bossut J; Fiant E; Frébourg T; Sabourin JC
Mod Pathol; 2011 Aug; 24(8):1090-100. PubMed ID: 21516079
[TBL] [Abstract][Full Text] [Related]
11. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhang X; Wang Y; Gao N; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
[TBL] [Abstract][Full Text] [Related]
12. KRAS and BRAF mutation analysis in colorectal adenocarcinoma specimens with a low percentage of tumor cells.
Lewandowska MA; Jóźwicki W; Żurawski B
Mol Diagn Ther; 2013 Jun; 17(3):193-203. PubMed ID: 23606169
[TBL] [Abstract][Full Text] [Related]
13. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
14. Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancer.
Dono M; Massucco C; Chiara S; Sonaglio C; Mora M; Truini A; Cerruti G; Zoppoli G; Ballestrero A; Truini M; Ferrarini M; Zupo S
Mol Med; 2013 Feb; 18(1):1519-26. PubMed ID: 23255073
[TBL] [Abstract][Full Text] [Related]
15. KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer.
Spindler KG; Appelt AL; Pallisgaard N; Andersen RF; Jakobsen A
Br J Cancer; 2013 Dec; 109(12):3067-72. PubMed ID: 24263065
[TBL] [Abstract][Full Text] [Related]
16. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W
Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850
[TBL] [Abstract][Full Text] [Related]
17. Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer.
Ličar A; Cerkovnik P; Novaković S
Med Oncol; 2011 Dec; 28(4):1048-53. PubMed ID: 20645028
[TBL] [Abstract][Full Text] [Related]
18. Mutation pattern of KRAS and BRAF oncogenes in colorectal cancer patients.
Rako I; Jakic-Razumovic J; Katalinic D; Sertic J; Plestina S
Neoplasma; 2012; 59(4):376-83. PubMed ID: 22489692
[TBL] [Abstract][Full Text] [Related]
19. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
[TBL] [Abstract][Full Text] [Related]
20. The proto-oncogene KRAS and BRAF profiles and some clinical characteristics in colorectal cancer in the Turkish population.
Ozen F; Ozdemir S; Zemheri E; Hacimuto G; Silan F; Ozdemir O
Genet Test Mol Biomarkers; 2013 Feb; 17(2):135-9. PubMed ID: 23297805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
